EGFR and glioblastoma: We compared WSD-0922 to erlotinib, a potent, well-characterized first-generation ATP-competitive inhibitor of EGFR.10,11 Although erlotinib received clinical approval for treatment of non-small cell lung cancer and pancreatic cancer, clinical trials for GBM have not been successful,12,13 potentially due to poor penetration across the BBB.